UPDATE 1-Ionis, Biogen say second study testing muscle drug succeeds

Nov 7 (Reuters) - Biogen Inc and Ionis

Pharmaceuticals said the second late-stage study of

their investigational treatment for a type of rare genetic

muscular disorder met its main goal in an interim analysis.

Read more